Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Narrow Path For Imports: Beware The 'SIP'-pery Slope

Executive Summary

Newly proposed pathway to allow states to pursue wholesale importation of drugs from Canada is extremely narrow and restrictive, at least in draft form. It is still a terrible precedent for industry – one that can be easily expanded if it takes effect.

You may also be interested in...



Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners

The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.

Florida Versus US FDA ... Again

The very public attempt by the state of Florida to question FDA’s decision on COVID monoclonal antibodies is the latest example of how the politics of COVID is roiling the agency’s reputation. But is it really so different than Florida’s pre-pandemic plans to import drugs from Canada?

US FDA Importation Proposal: Rigorous Requirements May Limit Impact

Proposed rule allowing states to import certain drugs from Canada would require tight supply chain, extensive security and reporting responsibilities. The potential costs and rigor involved in implementing the program could impede its uptake. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel